...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Cardiology >Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens
【24h】

Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens

机译：硒和辅酶Q10联合补充后，心血管疾病死亡率和N末端proBNP降低：瑞典老年人中一项为期5年的前瞻性随机双盲安慰剂对照试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Selenium and coenzyme Q10 are essential for the cell. Low cardiac contents of selenium and coenzyme Q10 have been shown in patients with cardiomyopathy, but inconsistent results are published on the effect of supplementation of the two components separately. A vital relationship exists between the two substances to obtain optimal function of the cell. However, reports on combined supplements are lacking. Methods: A 5-year prospective randomized double-blind placebo-controlled trial among Swedish citizens aged 70 to 88 was performed in 443 participants given combined supplementation of selenium and coenzyme Q10 or a placebo. Clinical examinations, echocardiography and biomarker measurements were performed. Participants were monitored every 6th month throughout the intervention. The cardiac biomarker N-terminal proBNP (NT-proBNP) and echocardiographic changes were monitored and mortalities were registered. End-points of mortality were evaluated by Kaplan-Meier plots and Cox proportional hazard ratios were adjusted for potential confounding factors. Intention-to-treat and per-protocol analyses were applied. Results: During a follow up time of 5.2 years a significant reduction of cardiovascular mortality was found in the active treatment group vs. The placebo group (5.9% vs. 12.6%; P = 0.015). NT-proBNP levels were significantly lower in the active group compared with the placebo group (mean values: 214 ng/L vs. 302 ng/L at 48 months; P = 0.014). In echocardiography a significant better cardiac function score was found in the active supplementation compared to the placebo group (P = 0.03). Conclusion: Long-term supplementation of selenium/coenzyme Q10 reduces cardiovascular mortality. The positive effects could also be seen in NT-proBNP levels and on echocardiography.
机译：背景：硒和辅酶Q10对细胞至关重要。心肌病患者的心脏硒和辅酶Q10含量较低，但分别补充这两种成分的效果却不一致。两种物质之间存在至关重要的关系，以获得最佳的细胞功能。但是，缺乏有关综合补品的报道。方法：在443名参与者中进行了一项为期5年的前瞻性随机双盲安慰剂对照试验，研究对象为年龄在70至88岁的瑞典公民，他们联合补充了硒和辅酶Q10或安慰剂。进行了临床检查，超声心动图和生物标志物测量。在整个干预过程中，每6个月对参与者进行一次监测。监测心脏生物标志物N端proBNP（NT-proBNP）和超声心动图的变化，并记录死亡率。通过Kaplan-Meier图评估死亡率的终点，并针对潜在的混杂因素调整Cox比例风险比。进行意向治疗和按方案分析。结果：在5.2年的随访期内，与安慰剂组相比，积极治疗组的心血管死亡率显着降低（5.9％对12.6％; P = 0.015）。与安慰剂组相比，活性组的NT-proBNP水平显着降低（平均值：在48个月时为214 ng / L与302 ng / L; P = 0.014）。在超声心动图检查中，与安慰剂组相比，在有效补给中发现了明显更好的心脏功能评分（P = 0.03）。结论：长期补充硒/辅酶Q10可降低心血管死亡率。在NT-proBNP水平和超声心动图上也可以看到积极的影响。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号